Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | GPR39 | O43194 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22529924 | 0.88 | AURKA (0.38) | CYP11B1CYP11B2NPC1RAB9AEGLN1 | |
| SCHEMBL29352030 | 0.88 | AURKA (0.38) | CYP11B1CYP11B2NPC1RAB9AEGLN1 | |
| SCHEMBL22529945 | 0.82 | CYP11B1 (0.49) | CYP11B1CYP11B2NPC1RAB9ATDP1 | |
| SCHEMBL29349924 | 0.82 | CYP11B1 (0.49) | CYP11B1CYP11B2NPC1RAB9ATDP1 | |
| SCHEMBL22530429 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL29351920 | 0.78 | CYP11B1 (0.45) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22530938 | 0.78 | CYP11B1 (0.45) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22530855 | 0.77 | CYP11B1 (0.50) | CYP11B1CYP11B2NPC1RAB9ABAZ2B | |
| SCHEMBL22529941 | 0.71 | SCN9A (0.41) | NPC1RAB9AEGLN1SMN1; SMN2MEN1 | |
| SCHEMBL28718883 | 0.71 | CYP11B1 (0.52) | CYP11B1CYP11B2NPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | disclosed |
| WO-2020208139-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | CELLESTIA BIOTECH AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020208139-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | CELLESTIA BIOTECH AG (CH) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | NOTCH1, NOTCH4, NOTCH2 | CYP11B1 2767/4885CYP11B2 3348/4885NPC1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.